Stock listing
NASDAQ:XBIO Xenetic Biosciences, Inc. Stock
Home listing (NASDAQ) of Xenetic Biosciences, Inc.
Follow Xenetic Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:XBIO
$1.40 USD -0.13 (-8.5%)
Close on Nov 20, 2026
- Day range
- $1.25 – $1.56 USDNov 20, 2026
- Volume
- 21,759 sharesNov 20, 2026
- Market cap
- $3.28M USDAt the close on Nov 20, 2026 · price × 2.34M shares outstanding
- 52-week range
- $1.25 – $4.94 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $193,658 USDMedian day 22,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:XBIO · Home | $1.40 USD | -0.13 (-8.5%) | 21,759 | $1.55 | $1.56 | $1.25 | $1.53 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:XBIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.40 | -0.13 | -8.5% | $1.55 | $1.56 | $1.25 | 21,759 | |
| $1.53 | -0.08 | -5.0% | $1.58 | $1.58 | $1.52 | 8,956 | |
| $1.61 | +0.12 | +8.1% | $1.59 | $1.61 | $1.54 | 9,791 | |
| $1.49 | -0.17 | -10.2% | $1.65 | $1.745 | $1.43 | 17,504 | |
| $1.66 | 0.00 | 0.0% | $1.765 | $1.837 | $1.66 | 9,666 | |
| $1.66 | -0.206 | -11.0% | $1.76 | $1.797 | $1.65 | 21,490 | |
| $1.866 | +0.066 | +3.7% | $1.77 | $1.90 | $1.77 | 3,780 | |
| $1.80 | +0.002 | +0.1% | $1.69 | $1.895 | $1.69 | 4,444 | |
| $1.798 | -0.073 | -3.9% | $1.85 | $1.948 | $1.798 | 2,541 | |
| $1.871 | +0.006 | +0.3% | $1.825 | $1.969 | $1.758 | 5,547 | |
| $1.865 | -0.145 | -7.2% | $1.99 | $1.99 | $1.78 | 36,228 | |
| $2.01 | -0.07 | -3.4% | $2.12 | $2.164 | $2.01 | 10,807 | |
| $2.08 | +0.02 | +1.0% | $2.06 | $2.127 | $2.02 | 11,455 | |
| $2.06 | +0.01 | +0.5% | $2.09 | $2.259 | $2.00 | 29,671 | |
| $2.05 | -0.07 | -3.3% | $2.14 | $2.15 | $1.95 | 32,564 | |
| $2.12 | +0.02 | +1.0% | $2.12 | $2.21 | $2.08 | 33,875 | |
| $2.10 | +0.275 | +15.1% | $1.95 | $2.135 | $1.89 | 136,342 | |
| $1.825 | -0.025 | -1.4% | $1.81 | $1.90 | $1.781 | 10,103 | |
| $1.85 | +0.13 | +7.6% | $1.70 | $1.859 | $1.58 | 45,666 | |
| $1.72 | -0.21 | -10.9% | $1.90 | $1.90 | $1.72 | 22,100 | |
| $1.93 | -0.09 | -4.5% | $2.03 | $2.04 | $1.90 | 18,900 | |
| $2.02 | +0.02 | +1.0% | $2.00 | $2.03 | $1.97 | 6,800 | |
| $2.00 | +0.07 | +3.6% | $1.96 | $2.05 | $1.96 | 11,500 | |
| $1.93 | -0.06 | -3.0% | $1.93 | $1.95 | $1.85 | 10,100 | |
| $1.99 | -0.02 | -1.0% | $1.98 | $2.00 | $1.92 | 17,500 | |
| $2.01 | -0.09 | -4.3% | $2.09 | $2.10 | $1.885 | 51,400 | |
| $2.10 | 0.00 | 0.0% | $2.07 | $2.14 | $2.07 | 12,600 | |
| $2.10 | -0.02 | -0.9% | $2.14 | $2.175 | $2.04 | 33,900 | |
| $2.12 | -0.01 | -0.5% | $2.14 | $2.27 | $2.11 | 8,500 | |
| $2.13 | +0.01 | +0.5% | $2.195 | $2.231 | $2.13 | 10,200 | |
| $2.12 | -0.09 | -4.1% | $2.18 | $2.18 | $2.10 | 13,600 | |
| $2.21 | +0.09 | +4.2% | $2.11 | $2.21 | $2.11 | 15,600 | |
| $2.12 | -0.08 | -3.6% | $2.19 | $2.341 | $2.10 | 14,700 | |
| $2.20 | -0.04 | -1.8% | $2.23 | $2.29 | $2.19 | 9,500 | |
| $2.24 | 0.00 | 0.0% | $2.30 | $2.33 | $2.11 | 43,200 | |
| $2.24 | -0.08 | -3.4% | $2.335 | $2.335 | $2.21 | 13,400 | |
| $2.32 | +0.06 | +2.7% | $2.26 | $2.335 | $2.22 | 30,400 | |
| $2.26 | -0.07 | -3.0% | $2.34 | $2.35 | $2.25 | 12,300 | |
| $2.33 | -0.06 | -2.5% | $2.37 | $2.475 | $2.23 | 34,700 | |
| $2.39 | -0.08 | -3.2% | $2.42 | $2.53 | $2.33 | 50,700 | |
| $2.47 | -0.05 | -2.0% | $2.56 | $2.56 | $2.28 | 64,000 | |
| $2.52 | -0.05 | -1.9% | $2.65 | $2.65 | $2.43 | 90,300 | |
| $2.57 | -0.42 | -14.0% | $2.99 | $2.99 | $2.436 | 152,600 | |
| $2.99 | +0.22 | +7.9% | $2.81 | $3.10 | $2.80 | 145,600 | |
| $2.77 | +0.31 | +12.6% | $2.50 | $2.80 | $2.30 | 413,700 | |
| $2.46 | +0.27 | +12.3% | $2.27 | $2.46 | $2.15 | 667,700 | |
| $2.19 | -2.08 | -48.7% | $2.75 | $2.789 | $1.87 | 1,514,500 | |
| $4.27 | -0.06 | -1.4% | $4.33 | $4.33 | $4.088 | 5,900 | |
| $4.33 | +0.43 | +11.0% | $4.00 | $4.33 | $3.852 | 66,800 | |
| $3.90 | -0.17 | -4.2% | $4.07 | $4.11 | $3.837 | 37,700 | |
| $4.07 | -0.145 | -3.4% | $4.15 | $4.20 | $4.06 | 15,500 | |
| $4.215 | -0.065 | -1.5% | $4.26 | $4.30 | $4.11 | 26,800 | |
| $4.28 | -0.39 | -8.4% | $4.67 | $4.76 | $4.00 | 86,000 | |
| $4.67 | +0.04 | +0.9% | $4.73 | $4.904 | $4.41 | 79,200 | |
| $4.63 | +0.38 | +8.9% | $4.27 | $4.939 | $4.27 | 139,100 | |
| $4.25 | +0.02 | +0.5% | $4.23 | $4.432 | $4.08 | 24,900 | |
| $4.23 | +0.04 | +1.0% | $4.20 | $4.25 | $4.00 | 25,900 | |
| $4.19 | +0.21 | +5.3% | $3.99 | $4.30 | $3.954 | 30,200 | |
| $3.98 | +0.01 | +0.3% | $4.01 | $4.06 | $3.90 | 19,600 | |
| $3.97 | +0.11 | +2.8% | $3.91 | $4.00 | $3.86 | 23,900 | |
| $3.86 | +0.04 | +1.0% | $3.78 | $3.88 | $3.70 | 22,400 | |
| $3.82 | +0.01 | +0.3% | $3.81 | $3.82 | $3.58 | 27,364 | |
| $3.81 | +0.22 | +6.1% | $3.74 | $4.05 | $3.53 | 102,789 | |
| $3.59 | +0.20 | +5.9% | $3.36 | $3.73 | $3.18 | 84,256 | |
| $3.39 | +0.03 | +0.9% | $3.41 | $3.41 | $3.28 | 9,269 |
Splits
2 splits since 2019 · NASDAQ:XBIO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-12 | Consolidation |
- Ticker
- NASDAQ:XBIO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
Latest deck · Sep 16, 2026
Merger or Acquisition (September 2026)
Merger or acquisition · 25 slides
Latest news
Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
Nov 13, 2026
Closed $1.66 (0.0%) on Nov 13, 2026
Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance
Nov 4, 2026
Closed $2.01 (-3.4%) on Nov 4, 2026
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
Oct 15, 2026
Closed $2.01 (-4.3%) on Oct 15, 2026
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Sep 16, 2026
Closed $2.19 (-48.7%) on Sep 16, 2026
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
Aug 7, 2026
Closed $3.17 (+11.2%) on Aug 7, 2026
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Jun 4, 2026
Closed $3.43 (+2.7%) on Jun 4, 2026
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
Jun 1, 2026
Closed $3.31 (+5.1%) on Jun 1, 2026
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
May 13, 2026
Closed $3.18 (+5.1%) on May 13, 2026
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
Apr 22, 2026
Closed $3.14 (+0.3%) on Apr 22, 2026
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
Mar 13, 2026
Closed $2.81 (+9.5%) on Mar 13, 2026
Xenetic Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 11 in the last 12 months · 103 in all · newest Nov 13, 2026 · oldest 2019
- Decks
- 8 decks · latest Sep 16, 2026
Where Xenetic Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:XBIO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:XBIO | BOATS | United States | USD |
| Munich:3XB0 | Munich | Germany | EUR |
| gettex:3XB0 | gettex | Germany | EUR |
Valuation
EV/sales −0.8× against a median of −12.8×: 3rd lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$2.53M USD
- P/E
- Loss
- EV/sales
- −0.8×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.7×
- Gross margin
- 16.7%
- Operating margin
- −129.6%
- Net margin
- −123.7%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.46
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Xenetic Biosciences, Inc. · NASDAQ:XBIO | US$3.28M | −US$2.53M | n/a | −0.8× | n/a | 0.7× | −123.7% | 0.0× | 1.46 |
| Liminatus Pharma, Inc. · NASDAQ:LIMN | US$3.37M | US$1.80M | n/a | n/a | n/a | 11.2× | n/a | 4.8× | 0.94 |
| Aprea Therapeutics, Inc. · NASDAQ:APRE | US$3.25M | −US$34.60M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.73 |
| Spago Nanomedical AB · OMXSTO:SPAGO | US$3.21M | US$22,125 | n/a | 5.6× | n/a | 1.0× | n/a | 0.0× | n/a |
| Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX | US$3.19M | −US$12.81M | n/a | −12.8× | n/a | 0.2× | n/a | 0.0× | 1.54 |
| Azitra Inc · AMEX:AZTR | US$3.13M | −US$618,677 | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.60 |
| NuCana plc · NASDAQ:NCNA | US$3.12M | −US$21.39M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.58 |
| Revive Therapeutics Ltd. · CSE:RVV | US$3.10M | US$3.14M | n/a | n/a | n/a | n/a | n/a | n/a | 0.56 |
| Skye Bioscience, Inc. · NASDAQ:SKYE | US$3.10M | −US$1.71M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 0.85 |
| Creative Medical Technology Holdings, Inc. · NASDAQ:CELZ | US$3.06M | −US$3.79M | n/a | −1,263× | n/a | 0.4× | n/a | 0.0× | 1.53 |
| Oncology Pharma Inc. · OTC:ONPH | US$3.04M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.62 |
| Median of the others | US$3.13M | −US$1.71M | −12.8× | 0.6× | 0.0× | 0.94 |
Forecasts
Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 40.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.32 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| James F. Parslow | Interim Chief Executive Officer and Chief Financial Officer |
Board
| Director | Role |
|---|---|
| Alexey Vinogradov | Non-Executive Director |
| Dmitry Genkin | Non-Executive Director |
| Firdaus Jal Dastoor | Non-Executive Director |
| Grigory G. Borisenko | Non-Executive Director |
| Moshe Mizrahy | Non-Executive Director |
| Roger Kornberg | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 | −11.1% |
| Q2 2026 | Aug 11, 2026 | +6.8% |
| Q1 2026 | May 13, 2026 | +2.8% |
| Q4 2025 | Mar 12, 2026 · After close | +9.5% |
| Q3 2025 | Nov 12, 2025 · After close | −2.6% |
| Q2 2025 | Aug 12, 2025 · After close | +7.2% |
| Q1 2025 | May 7, 2025 · After close | +0.3% |
| Q4 2024 | Mar 18, 2025 · After close | +1.9% |
| Q3 2024 | Nov 12, 2024 · After close | −11.6% |
| Q2 2024 | Aug 13, 2024 · After close | −6.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −3.6% |
| Q4 2023 | Mar 21, 2024 · After close | −2.3% |
| Q3 2023 | Nov 9, 2023 · After close | −1.4% |
| Q2 2023 | Aug 10, 2023 · After close | +0.8% |
| Q1 2023 | May 11, 2023 · After close | −17.5% |
| Q4 2022 | Mar 22, 2023 · After close | 0.0% |
| Q3 2022 | Nov 9, 2022 · After close | +4.3% |
| Q2 2022 | Aug 11, 2022 · After close | +4.8% |
| Q1 2022 | May 12, 2022 · After close | +6.5% |
| Q4 2021 | Mar 22, 2022 · After close | +4.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (September 2026) | Merger or acquisition | 25 slides | Sep 16, 2026 |
| Merger or Acquisition (September 2026) | Merger or acquisition | 26 slides | September 2026 |
| Investor Presentation (June 2023) | Investor deck | 30 slides | Jun 6, 2023 |
| Investor Presentation (September 2021) | Investor deck | 28 slides | Sep 13, 2021 |
| Investor Presentation (January 2021) | Investor deck | 24 slides | Jan 19, 2021 |
| Investor Presentation (September 2019) | Investor deck | 32 slides | Sep 9, 2019 |
| Corporate Update (June 2019) | Corporate update | 32 slides | Jun 18, 2019 |
| Merger or Acquisition (March 2019) | Merger or acquisition | 34 slides | Mar 4, 2019 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: about US$4.5M · US$6.12 a share · Canaccord Genuity Dealers: Canaccord Genuity (lead) Use of proceeds: Working capital and other general corporate purposes | Oct 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M | 436.9K | 17.1K | 0 | 7.58M | 3.00M |
| Cost of revenue | 27.0K | 35.5K | 15.8K | 156.1K | 36.4K | |||||
| Gross profit | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M | 436.9K | 17.1K | -15.8K | 7.43M | 2.96M |
| Research and development | 3.07M | 3.29M | 3.49M | 4.77M | 3.16M | 1.73M | 4.89M | 2.88M | 4.06M | 43.7M |
| Selling, general and administrative | 2.75M | 3.42M | 3.56M | 3.65M | 3.74M | 3.40M | 4.73M | 4.39M | 6.94M | 6.69M |
| Operating income | -2.83M | -4.20M | -4.52M | -6.72M | -5.75M | -13.9M | -12.9M | -7.28M | -3.57M | -47.4M |
| Depreciation and amortization | 153.3K | 0 | 0 | 0 | 1.00K | 4.20K | 15.8K | 23.8K | 36.4K | |
| EBITDA | -4.05M | -4.52M | -6.72M | -5.75M | -13.9M | -12.9M | -7.26M | -3.54M | -47.4M | |
| Interest expense | 165.6K | 101.6K | 18.4M | 111.8K | 24.1K | 1.82K | 729.6K | |||
| Income before tax | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M | -13.8M | -12.8M | -7.30M | -3.60M | -54.2M |
| Income tax | 0 | 0 | 0 | 0 | 0 | -2.92M | 0 | 0 | 0 | 0 |
| Net income | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M | -10.9M | -12.8M | -7.30M | -3.60M | -54.2M |
| Earnings per share, basic | -1.58 | -2.57 | -2.71 | -4.61 | -0.55 | -1.70 | -6.33 | -9.66 | -0.41 | -7.84 |
| Earnings per share, diluted | -1.58 | -2.57 | -2.71 | -4.61 | -0.55 | -1.70 | -6.33 | -9.66 | -0.41 | -7.84 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.88M | 6.17M | 8.98M | 13.1M | 18.2M | 11.5M | 10.4M | 571.6K | 5.53M | 4.05M |
| Short-term investments | 67.0K | 67.0K | ||||||||
| Receivables | 500.0K | 0 | 3.00M | |||||||
| Inventory | 1 | |||||||||
| Current assets | 8.05M | 6.59M | 9.59M | 13.7M | 18.7M | 12.4M | 11.1M | 1.19M | 5.88M | 8.34M |
| Property, plant and equipment | 0 | 0 | 0 | 757 | 4.96K | 27.8K | 42.4K | |||
| Goodwill | 0 | 9.24M | 3.28M | 3.28M | 3.28M | |||||
| Total assets | 8.36M | 6.90M | 10.6M | 14.7M | 19.8M | 13.2M | 21.5M | 14.4M | 19.2M | 21.0M |
| Accounts payable | 258.1K | 283.6K | 240.8K | 287.4K | 362.5K | 327.4K | 931.1K | 934.1K | 786.8K | 1.01M |
| Current liabilities | 968.0K | 894.3K | 809.6K | 1.07M | 1.42M | 936.9K | 1.42M | 1.60M | 1.94M | 1.87M |
| Total debt | 27.0K | 62.5K | 20.0K | |||||||
| Total liabilities | 968.0K | 894.3K | 809.6K | 1.07M | 1.42M | 964.0K | 4.33M | 4.52M | 4.86M | 4.80M |
| Shareholders' equity | 7.40M | 6.01M | 9.80M | 13.6M | 18.4M | 12.2M | 17.2M | 9.91M | 14.3M | 16.2M |
| Shares outstanding | 2.29M | 1.54M | 1.54M | 1.52M | 13.4M | 8.75M | 6.07M | 783.9K | 8.72M | 4.59M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -2.29M | -2.82M | -4.11M | -4.65M | -4.74M | -4.27M | -6.40M | -6.46M | 1.49M | -8.79M |
| Capital spending | 0 | 0 | -1 | -500.0K | 0 | 0 | 0 | 0 | -9.26K | -16.8K |
| Free cash flow | -2.29M | -2.82M | -4.11M | -5.15M | -4.74M | -4.27M | -6.40M | -6.46M | 1.48M | -8.80M |
| Cash from investing | 0 | -500.0K | 0 | 0 | 2.00K | 22.5K | -9.26K | -16.8K | ||
| Cash from financing | 4.00M | 0 | 16 | 0 | 11.5M | 5.43M | 16.1M | 1.48M | 0 | 12.7M |
| Dividends paid | -39.5M | |||||||||
| Share buybacks | 1.29M | 5.43M | 3.03M | 1.48M | 39.5M | |||||
| Change in cash | 1.72M | -2.82M | -4.11M | -5.15M | 6.72M | 1.16M | 9.73M | -4.96M | 1.48M | 3.92M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| DEFA14A · Additional proxy material | Nov 13, 2026 | Meeting notice | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 23, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 18, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 16, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 29, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 24, 2026 | Annual report | SEC |
| 8-K · Current report | Apr 24, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2026 | Results | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Dec 11, 2025 | Meeting notice | SEC |
| 8-K · Current report | Dec 11, 2025 | Current report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Oct 31, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Oct 31, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 31, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 14, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 10, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Oct 10, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | May 13, 2025 | Annual report | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2025 | Annual report | SEC |
| 8-K · Current report | Apr 10, 2025 | Current report | SEC |
| 8-K/A · Current report, amended | Mar 19, 2025 | Current report | SEC |
| 8-K · Current report | Mar 19, 2025 | Results | SEC |
| 10-K · Annual report | Mar 18, 2025 | Annual report | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 13, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Nov 4, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 31, 2024 | Management or board change | SEC |
| ARS · Annual report to shareholders | Oct 31, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Oct 31, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 31, 2024 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Oct 30, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 25, 2024 | Other filings | SEC |
| S-3 · Registration statement | Oct 21, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 25-NSE | Jul 18, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 21, 2024 | Management or board change | SEC |
| 8-K · Current report | May 22, 2024 | Management or board change | SEC |
| 8-K · Current report | May 10, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 26, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 22, 2024 | Results | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 18, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 8, 2023 | Meeting outcome | SEC |
| ARS · Annual report to shareholders | Nov 13, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 13, 2023 | Meeting notice | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 18, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Aug 11, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| SC 13D · Big-stake notice | Jun 15, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jun 6, 2023 | Current report | SEC |
| 8-K · Current report | Jun 2, 2023 | Current report | SEC |
| 8-K · Current report | May 12, 2023 | Current report | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 23, 2023 | Results | SEC |
| 10-K · Annual report | Mar 22, 2023 | Annual report | SEC |
| 8-K · Current report | Dec 22, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | Dec 9, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2022 | Insider trade | SEC |
| 8-K · Current report | Dec 9, 2022 | Meeting outcome | SEC |
| 8-K · Current report | Dec 2, 2022 | Current report | SEC |
| 8-K · Current report | Nov 10, 2022 | Results | SEC |
| 10-Q · Quarterly report | Nov 9, 2022 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Oct 21, 2022 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Oct 17, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 17, 2022 | Meeting notice | SEC |
| D | Oct 13, 2022 | Other filings | SEC |
| 8-K · Current report | Oct 12, 2022 | Financing | SEC |
| PRE 14A · Preliminary proxy statement | Oct 3, 2022 | Meeting notice | SEC |
| 8-K · Current report | Aug 12, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2022 | Quarterly report | SEC |
| 8-K · Current report | Jul 7, 2022 | Material contract | SEC |
| 8-K · Current report | Jun 6, 2022 | Current report | SEC |
| 10-Q · Quarterly report | May 12, 2022 | Quarterly report | SEC |
| D | May 4, 2022 | Other filings | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2022 | Annual report | SEC |
| 8-K · Current report | Apr 27, 2022 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Mar 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2022 | Insider trade | SEC |
| 8-K · Current report | Mar 23, 2022 | Results | SEC |
| 10-K · Annual report | Mar 22, 2022 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Dec 30, 2021 | Offer document | SEC |
| 4 · Change in ownership | Dec 9, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2021 | Insider trade | SEC |
| 8-K · Current report | Dec 9, 2021 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Dec 2, 2021 | Meeting notice | SEC |
| 8-K · Current report | Nov 19, 2021 | Material contract | SEC |
| 424B5 · Prospectus | Nov 19, 2021 | Offer document | SEC |
| 8-K · Current report | Nov 16, 2021 | Material contract | SEC |
| 8-K · Current report | Nov 12, 2021 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2021 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Oct 25, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 20, 2021 | Other filings | SEC |
| S-3/A · Registration statement, amended | Oct 20, 2021 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Oct 19, 2021 | Other filings | SEC |
| DEF 14A · Proxy statement | Oct 15, 2021 | Meeting notice | SEC |
| 8-K · Current report | Oct 15, 2021 | Material contract | SEC |
| S-3 · Registration statement | Oct 12, 2021 | Offer document | SEC |
| 8-K · Current report | Sep 13, 2021 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 24, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 19, 2021 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 18, 2021 | Other filings | SEC |
| S-3 · Registration statement | Aug 13, 2021 | Offer document | SEC |
| 8-K · Current report | Aug 13, 2021 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2021 | Quarterly report | SEC |
| D | Aug 3, 2021 | Other filings | SEC |
| 8-K · Current report | Jul 28, 2021 | Material contract | SEC |
| 8-K · Current report | Jul 16, 2021 | Management or board change | SEC |
| 8-K · Current report | May 12, 2021 | Results | SEC |
| 10-Q · Quarterly report | May 11, 2021 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2021 | Annual report | SEC |
| 4 · Change in ownership | Mar 22, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Mar 22, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Mar 22, 2021 | Insider trade | SEC |
| 8-K · Current report | Mar 17, 2021 | Results | SEC |
| 10-K · Annual report | Mar 16, 2021 | Annual report | SEC |
| 8-K · Current report | Jan 19, 2021 | Current report | SEC |
| SC 13G · Big-stake notice | Dec 21, 2020 | Big-stake notice | SEC |
| 8-K · Current report | Dec 16, 2020 | Current report | SEC |
| 8-K · Current report | Dec 14, 2020 | Material contract | SEC |
| 424B5 · Prospectus | Dec 11, 2020 | Offer document | SEC |
| 8-K · Current report | Dec 9, 2020 | Meeting outcome | SEC |
| 4 · Change in ownership | Dec 8, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2020 | Insider trade | SEC |
| 8-K · Current report | Nov 13, 2020 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2020 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2020 | Current report | SEC |
| UPLOAD · Letter from the SEC | Oct 14, 2020 | Other filings | SEC |
| DEF 14A · Proxy statement | Oct 13, 2020 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Oct 6, 2020 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 5, 2020 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Sep 30, 2020 | Meeting notice | SEC |
| 8-K · Current report | Aug 13, 2020 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2020 | Quarterly report | SEC |
| 8-K · Current report | Jun 24, 2020 | Current report | SEC |
| 8-K · Current report | Jun 16, 2020 | Material contract | SEC |
| 8-K · Current report | May 19, 2020 | Material contract | SEC |
| 10-Q · Quarterly report | May 14, 2020 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2020 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2020 | Annual report | SEC |
| 8-K · Current report | Apr 24, 2020 | Current report | SEC |
| 4/A · Change in ownership, amended | Apr 2, 2020 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Apr 1, 2020 | Offer document | SEC |
| 8-K · Current report | Mar 27, 2020 | Results | SEC |
This page holds 200 of 488 filings. Open Filings
Cap table
Built by 6ix from Xenetic Biosciences, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 2,343,181
- Fully diluted
- 2,343,181
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 2,343,181 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 2,343,181 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Darlene Deptula-Hicks Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Jun 9, 2026); T2 Biosystems, Inc. (SVP & Chief Financial Officer · May 1, 2017 – Jun 6, 2017 · Past); Palvella Therapeutics, Inc. (SVP, Chief Financial Officer · Jun 29, 2015 – Jun 13, 2016 · Past); icad inc (Exec VP of Finance, CFO · Sep 11, 2006 – Mar 29, 2011 · Past) | Director · Nov 1, 2016 – Aug 9, 2017 · Past |
| Adam Logal Other companies: Non-Invasive Monitoring Systems, Inc. (Director · Since at least Sep 3, 2025); OPKO Health, Inc. (Sr. Vice President, CFO · Since at least Feb 19, 2021) | Director · Dec 4, 2020 – Dec 6, 2023 · Past |
| Edward J Benz Jr Other companies: Candel Therapeutics, Inc. (Director · Since at least Jul 26, 2021); Deciphera Pharmaceuticals LLC (Director · Sep 27, 2017 – Jun 11, 2024 · Past) | Director · Nov 21, 2016 – Aug 9, 2017 · Past |
| Roger Kornberg Other companies: Cocrystal Pharma, Inc. (Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board · Since at least Mar 17, 2014); Big Digital Energy, Inc. (Director · Jun 11, 2013 – Jun 11, 2013 · Past) | Non-Executive Director · Since at least Nov 1, 2016 |
| Curtis Lockshin Other companies: Phio Pharmaceuticals Corp. (Director · Since at least Mar 1, 2021) | Chief Sciencific Officer · Dec 4, 2019 – Dec 11, 2023 · Past |
| James F. Parslow Other companies: World Energy Solutions Inc (CFO, Treasurer, Secretary · Apr 22, 2009 – Jan 5, 2015 · Past) | Interim Chief Executive Officer and Chief Financial Officer · Since at least Apr 3, 2017 |
| Jeffrey F Eisenberg Other companies: MabVax Therapeutics Holdings Inc (Director · Feb 19, 2016 – Feb 21, 2018 · Past) | Chief Executive Officer, Director · Nov 1, 2016 – Dec 11, 2023 · Past |
| Moshe Mizrahy Other companies: InMode Ltd. (Chief Executive Officer, Director · Since at least Mar 18, 2026) | Non-Executive Director · Since at least Dec 6, 2023 |
| Alexey Vinogradov | Non-Executive Director · Since at least Jul 19, 2019 |
| Dmitry Genkin | Non-Executive Director · Since at least Aug 14, 2017 |
All 14 people
| Person | Seat |
|---|---|
| Firdaus Jal Dastoor | Non-Executive Director · Since at least Nov 1, 2016 |
| Grigory G. Borisenko | Director · Since at least Dec 7, 2022 |
| James Eric Callaway | Director · Dec 4, 2019 – Dec 6, 2023 · Past |
| Michael Scott Maguire | CEO, Director · Nov 1, 2016 – Dec 20, 2016 · Past |
Log in to ask 6ix AI your own questions about Xenetic Biosciences, Inc.